Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | JX-594 |
Trade Name | |
Synonyms | Pexastimogene devacirepvec|JX594|Pexa-vec|TG-6006 |
Drug Descriptions |
Pexastimogene devacirepvec (JX-594) is a thymidine kinase-inactivated oncolytic vaccinia virus expressing human GM-CSF, which selectively infects transformed cells and induces cell death (PMID: 22186794). |
DrugClasses | |
CAS Registry Number | 1058624-46-6 |
NCIT ID | C71533 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Avelumab + Cyclophosphamide + JX-594 | Avelumab Cyclophosphamide JX-594 | 0 | 1 |
Cemiplimab + JX-594 | Cemiplimab JX-594 | 0 | 1 |
Cyclophosphamide + JX-594 | Cyclophosphamide JX-594 | 0 | 1 |
Ipilimumab + JX-594 | Ipilimumab JX-594 | 0 | 1 |
JX-594 | JX-594 | 0 | 1 |
JX-594 + Sirolimus | JX-594 Sirolimus | 0 | 0 |
JX-594 + Sorafenib | JX-594 Sorafenib | 0 | 0 |
JX-594 + Sunitinib | JX-594 Sunitinib | 0 | 0 |